Volume 25, Number 1—January 2019
Research
Risk Factors for Elizabethkingia Acquisition and Clinical Characteristics of Patients, South Korea
Table 5
Results of univariable and multivariable analyses of risk factors for in-hospital mortality of patients with a true pathogen of Elizabethkingia in a tertiary teaching hospital, Seoul, South Korea
In-hospital mortality |
Total, n = 30 |
Survived, n = 20 |
Died, n = 10 |
p value |
Median age, y (range) | 68.5 (61.0–80.0) | 69.5 (60.5–79.5) | 66.5 (63.0–80.0) | 0.86 |
Male sex, no. (%) | 19 (63.3) | 11 (55.0) | 8 (80.0) | 0.35 |
Patients from the 3 study wards, no. (%) | 7 (23.3) | 5 (25.0) | 2 (20.0) | 0.99 |
Nosocomial infection, no. (%) | 29 (96.7) | 19 (95.0) | 10 (100.0) | 0.99 |
Median Charlson comorbidity index (range) |
6 (5.0–9.0) |
6 (4.5–7.5) |
6 (5.0–9.0) |
0.93 |
Clinical condition | ||||
Median hospitalization day of acquisition (range) | 26.5 (13.0–58.0) | 20.5 (12.0–32.0) | 52.5 (26.0–81.0) | 0.03 |
Median length of hospitalization, d (range) | 47.5 (29.0–89.0) | 38.5 (27.5–67.5) | 77.5 (54.0–210.0) | 0.04 |
Mechanical ventilation, no. (%) | 24 (80.0) | 15 (75.0) | 9 (90.0) | 0.63 |
Steroid use, no. (%) |
14 (46.7) |
9 (45.0) |
5 (50.0) |
0.99 |
Antimicrobial treatment, no. (%) | ||||
Penicillin* | 5 (16.7) | 3 (15.0) | 2 (20.0) | 0.99 |
1st-generation cephalosporin | 3 (10) | 2 (10.0) | 1 (10.0) | 0.99 |
2nd-generation cephalosporin | 5 (16.7) | 4 (20.0) | 1 (10.0) | 0.86 |
3rd-generation cephalosporin | 8 (26.7) | 4 (20.0) | 4 (40.0) | 0.47 |
4th-generation cephalosporin | 7 (23.3) | 4 (20.0) | 3 (30.0) | 0.88 |
Aminoglycoside | 1 (3.3) | 1 (5.0) | 0 | 0.99 |
Glycopeptide | 13 (43.3) | 6 (30.0) | 7 (70.0) | 0.09 |
Linezolid | 4 (13.3) | 2 (10.0) | 2 (20.0) | 0.85 |
Carbapenem | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
Tetracycline | 8 (26.7) | 7 (35.0) | 1 (10.0) | 0.30 |
Colistin | 3 (10) | 0 | 3 (30.0) | 0.05 |
Trimethoprim/sulfamethoxazole | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
Lincosamide | 5 (16.7) | 1 (5.0) | 4 (40.0) | 0.06 |
Macrolide | 1 (3.3) | 0 | 1 (10.0) | 0.72 |
Fluoroquinolone | 9 (30) | 4 (20.0) | 5 (50.0) | 0.21 |
Other | 5 (16.7) | 2 (10.0) | 3 (30.0) | 0.39 |
*Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
1These authors contributed equally to this article.